HER2-positive male breast cancer: An update

Antonio Russo, Sergio Rizzo, Giuseppe Bronte, Carlo Capalbo, Piera Rizzolo, Valentina Silvestri, Laura Ottini

Risultato della ricerca: Article

13 Citazioni (Scopus)

Abstract

Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cases are more often hormonal receptor (estrogen receptor/progesterone receptor [ER/PR]) positive and human epidermal growth factor receptor 2 (HER2) negative. Treatment of MBC patients follows the same indications as female postmenopausal with surgery, systemic therapy, and radiotherapy. To date, ER/PR and HER2 status provides baseline predictive information used in selecting optimal adjuvant/neoadjuvant therapy and in the selection of therapy for recurrent or metastatic disease. HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin®; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb®, GlaxoSmithKline, London, UK]) are currently under clinical evaluation. Particularly, trastuzumab, a monoclonal antibody which selectively binds the extracellular domain of HER2, has become an important therapeutic agent for women with HER2-positive (HER2+) BC. Currently, data regarding the use of trastuzumab in MBC patients is limited and only few case reports exist. In all cases, MBC patients received trastuzumab concomitantly with other drugs and no severe toxicity above grade 3 was observed. However, MBC patients that would be candidate for trastuzumab therapy (ie, HER2+/ER+ or HER2+/ER- MBCs) represent only a very small percentage of MBC cases. This is noteworthy, when taking into account that trastuzumab is an important and expensive component of systemic BC therapy. Since there is no data supporting the fact that response to therapy is different for men or women, we concluded that systemic therapy in MBC should be considered on the same basis as for FBC. Particularly in male patients, trastuzumab should be considered exclusively for advanced disease or high-risk HER2+ early BCs. On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.
Lingua originaleEnglish
pagine (da-a)45-58
Numero di pagine14
RivistaBREAST CANCER
Volume2
Stato di pubblicazionePublished - 2010

Fingerprint

Male Breast Neoplasms
Breast Neoplasms
Therapeutics
Progesterone Receptors
Estrogen Receptors
human ERBB2 protein
Trastuzumab
Neoadjuvant Therapy
Age Distribution
Switzerland
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Radiotherapy
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

Russo, A., Rizzo, S., Bronte, G., Capalbo, C., Rizzolo, P., Silvestri, V., & Ottini, L. (2010). HER2-positive male breast cancer: An update. BREAST CANCER, 2, 45-58.

HER2-positive male breast cancer: An update. / Russo, Antonio; Rizzo, Sergio; Bronte, Giuseppe; Capalbo, Carlo; Rizzolo, Piera; Silvestri, Valentina; Ottini, Laura.

In: BREAST CANCER, Vol. 2, 2010, pag. 45-58.

Risultato della ricerca: Article

Russo, A, Rizzo, S, Bronte, G, Capalbo, C, Rizzolo, P, Silvestri, V & Ottini, L 2010, 'HER2-positive male breast cancer: An update', BREAST CANCER, vol. 2, pagg. 45-58.
Russo A, Rizzo S, Bronte G, Capalbo C, Rizzolo P, Silvestri V e altri. HER2-positive male breast cancer: An update. BREAST CANCER. 2010;2:45-58.
Russo, Antonio ; Rizzo, Sergio ; Bronte, Giuseppe ; Capalbo, Carlo ; Rizzolo, Piera ; Silvestri, Valentina ; Ottini, Laura. / HER2-positive male breast cancer: An update. In: BREAST CANCER. 2010 ; Vol. 2. pagg. 45-58.
@article{f9e1463e9307458abe1099732af3fe1a,
title = "HER2-positive male breast cancer: An update",
abstract = "Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cases are more often hormonal receptor (estrogen receptor/progesterone receptor [ER/PR]) positive and human epidermal growth factor receptor 2 (HER2) negative. Treatment of MBC patients follows the same indications as female postmenopausal with surgery, systemic therapy, and radiotherapy. To date, ER/PR and HER2 status provides baseline predictive information used in selecting optimal adjuvant/neoadjuvant therapy and in the selection of therapy for recurrent or metastatic disease. HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin{\circledR}; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb{\circledR}, GlaxoSmithKline, London, UK]) are currently under clinical evaluation. Particularly, trastuzumab, a monoclonal antibody which selectively binds the extracellular domain of HER2, has become an important therapeutic agent for women with HER2-positive (HER2+) BC. Currently, data regarding the use of trastuzumab in MBC patients is limited and only few case reports exist. In all cases, MBC patients received trastuzumab concomitantly with other drugs and no severe toxicity above grade 3 was observed. However, MBC patients that would be candidate for trastuzumab therapy (ie, HER2+/ER+ or HER2+/ER- MBCs) represent only a very small percentage of MBC cases. This is noteworthy, when taking into account that trastuzumab is an important and expensive component of systemic BC therapy. Since there is no data supporting the fact that response to therapy is different for men or women, we concluded that systemic therapy in MBC should be considered on the same basis as for FBC. Particularly in male patients, trastuzumab should be considered exclusively for advanced disease or high-risk HER2+ early BCs. On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.",
keywords = "Lapatinib; Target therapy; Trastuzumab; Oncology",
author = "Antonio Russo and Sergio Rizzo and Giuseppe Bronte and Carlo Capalbo and Piera Rizzolo and Valentina Silvestri and Laura Ottini",
year = "2010",
language = "English",
volume = "2",
pages = "45--58",
journal = "Breast Cancer: Targets and Therapy",
issn = "1179-1314",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - HER2-positive male breast cancer: An update

AU - Russo, Antonio

AU - Rizzo, Sergio

AU - Bronte, Giuseppe

AU - Capalbo, Carlo

AU - Rizzolo, Piera

AU - Silvestri, Valentina

AU - Ottini, Laura

PY - 2010

Y1 - 2010

N2 - Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cases are more often hormonal receptor (estrogen receptor/progesterone receptor [ER/PR]) positive and human epidermal growth factor receptor 2 (HER2) negative. Treatment of MBC patients follows the same indications as female postmenopausal with surgery, systemic therapy, and radiotherapy. To date, ER/PR and HER2 status provides baseline predictive information used in selecting optimal adjuvant/neoadjuvant therapy and in the selection of therapy for recurrent or metastatic disease. HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin®; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb®, GlaxoSmithKline, London, UK]) are currently under clinical evaluation. Particularly, trastuzumab, a monoclonal antibody which selectively binds the extracellular domain of HER2, has become an important therapeutic agent for women with HER2-positive (HER2+) BC. Currently, data regarding the use of trastuzumab in MBC patients is limited and only few case reports exist. In all cases, MBC patients received trastuzumab concomitantly with other drugs and no severe toxicity above grade 3 was observed. However, MBC patients that would be candidate for trastuzumab therapy (ie, HER2+/ER+ or HER2+/ER- MBCs) represent only a very small percentage of MBC cases. This is noteworthy, when taking into account that trastuzumab is an important and expensive component of systemic BC therapy. Since there is no data supporting the fact that response to therapy is different for men or women, we concluded that systemic therapy in MBC should be considered on the same basis as for FBC. Particularly in male patients, trastuzumab should be considered exclusively for advanced disease or high-risk HER2+ early BCs. On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.

AB - Although rare, male breast cancer (MBC) remains a substantial cause for morbidity and mortality in men. Based on age frequency distribution, age-specific incidence rate pattern, and prognostic factor profiles, MBC is considered similar to postmenopausal breast cancer (BC). Compared with female BC (FBC), MBC cases are more often hormonal receptor (estrogen receptor/progesterone receptor [ER/PR]) positive and human epidermal growth factor receptor 2 (HER2) negative. Treatment of MBC patients follows the same indications as female postmenopausal with surgery, systemic therapy, and radiotherapy. To date, ER/PR and HER2 status provides baseline predictive information used in selecting optimal adjuvant/neoadjuvant therapy and in the selection of therapy for recurrent or metastatic disease. HER2 represents a very interesting molecular target and a number of compounds (trastuzumab [Herceptin®; F. Hoffmann-La Roche, Basel, Switzerland] and lapatinib [Tykerb®, GlaxoSmithKline, London, UK]) are currently under clinical evaluation. Particularly, trastuzumab, a monoclonal antibody which selectively binds the extracellular domain of HER2, has become an important therapeutic agent for women with HER2-positive (HER2+) BC. Currently, data regarding the use of trastuzumab in MBC patients is limited and only few case reports exist. In all cases, MBC patients received trastuzumab concomitantly with other drugs and no severe toxicity above grade 3 was observed. However, MBC patients that would be candidate for trastuzumab therapy (ie, HER2+/ER+ or HER2+/ER- MBCs) represent only a very small percentage of MBC cases. This is noteworthy, when taking into account that trastuzumab is an important and expensive component of systemic BC therapy. Since there is no data supporting the fact that response to therapy is different for men or women, we concluded that systemic therapy in MBC should be considered on the same basis as for FBC. Particularly in male patients, trastuzumab should be considered exclusively for advanced disease or high-risk HER2+ early BCs. On the other hand, lapatinib (Tykerb), a novel oral dual tyrosine kinase inhibitor that targets both HER2 and epidermal growth factor receptor, may represent an interesting and promising therapeutic agent for trastuzumab-resistant MBC patients.

KW - Lapatinib; Target therapy; Trastuzumab; Oncology

UR - http://hdl.handle.net/10447/212964

UR - http://www.dovepress.com/her2-positive-male-breast-cancer-an-update-peer-reviewed-article-BCTT

M3 - Article

VL - 2

SP - 45

EP - 58

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

SN - 1179-1314

ER -